Stamaril1000 IU/0.5 ml

Prophylaxis of Yellow fever infection

Vaccines, Anti-sera & Immunoglobulin

Live, attenuated virus stimulates active immunity to Yellow fever; conveys active immunity via stimulation of production of endogenously produced antibodies. Yellow fever vaccine is used for active immunisation against yellow fever. Each dose (usually 0.5 ml) contains at least 1000 mouse LD50 units.

Primary Vaccination: Adults and Children >9 months: 0.5 mL of reconstituted vaccine administered as a single dose. Children : The vaccine must not be given to children The vaccine should be given at least 10 days before entering an endemic area since protective immunity may not be achieved until at least this time has elapsed.Elderly: The dose is the same as for adults. However, due to a higher risk of Stamaril 1000 IU/0.5 ml-associated severe and potentially fatal disease in persons from 60 years of age, the vaccine should only be given when it is considered that there is a considerable and unavoidable risk of acquiring yellow fever infection.Re-Vaccination: Re-vaccination with 1 dose of 0.5 mL is recommended every 10 years in persons considered to be at risk of exposure. International Health Regulations (IHR) require re-vaccination, using the same dose as for primary vaccination, at intervals of 10 years in order to retain a valid certificate.For IM use, the recommended injection sites are the anterolateral aspect of the thigh in the infants and toddlers (6 months up to 2 years of age) and the deltoid muscle in older children and adults.

Immunosuppressants eg. cytotoxic agents, systemic steroids.

Hypersensitivity reaction to eggs, chicken proteins or to any component of this vaccine. Serious hypersensitivity reactions (eg, anaphylaxis) after a previous dose of any Stamaril 1000 IU/0.5 ml. Immunosuppression, whether congenital, idiopathic or as a result of treatment with systemic steroids (greater than the standard dose of topical or inhaled steroids), radiotherapy or cytotoxic drugs. History of thymus dysfunction (including thymoma, thymectomy). Symptomatic HIV infection. Asymptomatic HIV infection when accompanied by evidence of impaired immune function (see Precautions). Age Current severe febrile illness.

Fever, headache, seizure, myalgia, weakness, focal neurological defects. Local inj site reactions e.g. erythema, pain, oedema.

Pregnancy Category D. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).Lactation: There is a theoretical risk of transmission of vaccine components to the infants from breast-feeding mothers, lactation constitutes a contraindication, particularly when infants are <9 months of age because of the risk of encephalitis

Caution when used in immunocompromised patients e.g. patients receiving chemo-radiation therapy or other immunosuppressive therapy such as high-dose corticosteroids and patients 65 yr. Monitor for adverse events 10-30 days post-vaccination.